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While direct-acting antivirals (DAAs) for hepatitis C virus (HCV) have dramatically progressed, 
patients still suffer from treatment failures. For the radical eradication of HCV, a deeper understanding 
of multiple resistance-associated substitutions (RASs) at the single-clone level is essential. To 
understand HCV quasispecies and their dynamics during DAA treatment, we applied single-molecule 
real-time (SMRT) deep sequencing on sera from 12 patients with genotype-1b HCV infections with 
DAA treatment failures, both pre- and post-treatment. We identified > 3.2 kbp sequences between NS3 
and NS5A genes of 187,539 clones in total, classifying into haplotype codes based on the linkage of 
seven RAS loci. The number of haplotype codes during the treatment, per sample, significantly 
decreased from 14.67 ± 9.12 to 6.58 ± 7.1, while the number of nonsynonymous codons on the 
seven RAS loci, per clone, significantly increased from 1.50 ± 0.92 to 3.64 ± 0.75. In five cases, 
the minority multi-drug resistant haplotypes at pre-treatment were identical to the major haplotypes at 
relapse. Moreover, various structural variations (SVs) were detected and their dynamics analysed. 
These results suggest that SMRT deep sequencing is useful for detecting minority haplotypes and SVs, 
and to evaluate the dynamics of viral genomes at the single-clone level.  
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Introduction 
 The hepatitis C virus (HCV) has approximately 9.6 kb of a single-stranded RNA genome. After the 
approval of oral direct-acting antivirals (DAAs), after drastic HCV treatment, levels of HCV-RNA 
remain undetectable (sustained virological response; SVR) in most patients chronically infected by 
HCV or suffering from HCV-related diseases1,2,3,4,5. In some patients, however, DAAs cannot 
completely eradicate HCV1,2,3,4. 
One of the major causes of HCV survival during DAA treatment is thought to be a mutation of its 
genome. Mutations are likely to occur in the HCV genome due to the fact that RNA-dependent RNA 
polymerase lacks a proofreading function. Therefore, during HCV infection, the population of HCV 
includes similar but slightly different clones, and HCV is therefore known as a quasispecies6,7. Some 
quasispecies have resistance-associated substitutions (RASs) and make the DAAs ineffective. For 
example, Y93H on the NS5A gene is associated with the resistance of NS5A inhibitors8,9,10,11, while 
the inframe deletion of the NS5A-P32 codon leads to the failure of glecaprevir and pibrentasvir 
treatments12,13,14,15. Besides these resistance mutations, Q80/D168 on the NS3 gene and R30/L31/Q54 
on the NS5A gene are associated with RASs in HCV16,17. The antiviral treatment of patients after liver 
transplantation, or of those with liver cirrhosis, is still challenging, and to achieve SVR in some of 
these cases, drug-resistant HCV must be overcome3,18. Thus, a deeper understanding of multi-drug 
resistant HCV clones and their genetic landscape is important for the radical eradication of HCV in all 
cases.  
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To date, Sanger sequencing and second-generation sequencing, such as Miseq/Hiseq (Illumina, San 
Diego, USA) and Roche 454 sequencing (Roche 454 Life Sciences, Branford, CT, USA), have 
traditionally been used to determine genome variants19,20. However, these sequencers have the 
following limitations: (1) although these sequencing technologies output accurate sequences, Sanger 
sequencing cannot distinguish rare variants from noise21; (2) second-generation sequencers produce 
reads that are too short (paired-end 2 × 300 bp reads by Miseq/Hiseq and single-end 700 bp reads by 
Roche 454 sequencing) to determine multiple RASs from NS3 and NS5A genes (3.2 kbp) on the same 
genomic regions (linkage); (3) neither sequencer can detect large structural variations (SVs). In 
contrast, to detect multiple RASs and SVs at a single viral clone level of resolution, deep sequencing 
using third-generation long-read sequencers, including the PacBio RS II/Sequel (Pacific Biosciences, 
Menlo Park, CA, USA) and the Nanopore sequencer (Oxford Nanopore Technologies, Oxford, United 
Kingdom), is considered necessary. These sequencing technologies generate reads of over 10 kbp22,23. 
While the accuracy of the raw sequence reads from third-generation sequencers is limited to 90%, a 
characteristic error correction methodology by the PacBio sequencer system, called circular consensus 
sequencing (CCS) technology, improves the accuracy of the raw reads to as high as 99.9%24. Due to 
these characteristics, the PacBio RS II/Sequel can produce high quality sequence reads of HCV 
genomes at the single-molecule level, including multiple RASs, rare RASs, and SVs.  
Recently, we reported a methodology to evaluate viral quasispecies using the PacBio RSII 
sequencer25. We analysed the linkage of several RASs of NS3 and NS5A together, with a number of 
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synonymous substitutions at the single viral clone level. Through phylogenetic analysis using the 
genetic information of hundreds of viral clones in each serum, we demonstrated that multi-drug 
resistant viral clones could arise from pre-existing minority populations of drug-resistant variants. 
Although these analytical methods could be useful in unveiling the genetic basis of the evolution of 
multi-drug resistant viral clones, there is a need to simplify PacBio sequencing output to provide usable 
and clinically useful information. 
Therefore, in this study, we aimed to establish an analytical method to convert the sequencing data 
from long-read deep sequencing into lower-dimensional haplotype data, using the linkage of seven 
RAS-related loci and to analyse the data from the numerous viral haplotypes in each sample. Taking 
advantage of the long-read sequencer, we also explored SVs in each of the HCV genome sequences. 
Furthermore, using the sequence data at the single viral clone level, we examined the dynamics of 
the RAS-based haplotypes and the SVs pre- and post-treatment with DAA in treatment failures.  
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Results 
Single-molecule real-time sequencing of the region from the NS3 to the NS5A genes in the HCV 
genome 
We conducted SMRT sequencing for the 35 HCV-samples and obtained a total of 9,342,760 raw 
reads with 25,251,529,303 bp (Figure 1, Supplementary Table S1). To obtain more accurate reads, 
we executed a Consensus Circular Sequencing 2 (CCS2) algorithm on the error-prone raw reads using 
the pbsmrtpipe software (Pacific Biosciences). The CCS2 algorithm interlaces all raw reads (called 1-
pass when only one raw read was sequenced from one adapter to another adapter, and called 2-pass 
when two raw reads were sequenced from one adapter to another adapter) derived from the same DNA 
template. The pbsmrtpipe and blastn software, and the in-house perl script generated a total of 284,565 
≥ 5-pass CCS2 reads with primer sequences at each end (888,923,070 bp). The CCS2 reads were 
equivalent to a 7,516×  coverage, on average, of the region between the NS3 and NS5A genes 
(Supplementary Figure S1). The mean quality value of the ≥ 5 pass-CCS2 reads was high, at 55.4 - 
73.93, and the sequencing error rate was low, at 2.88 x 10-6-4.05 x 10-8 %.  
To assess the error rate in the whole procedure, we used two samples of HCV-containing plasmid as 
the control sequence. SMRT sequencing generated a total of 819,416 raw reads of the NS3-to-NS5A 
region with 2,177,357,653 bp. After error correction by the CCS2 algorithm, we obtained 38,364 ≥ 5-
pass CCS2 reads (101,683,536 bp). These ≥ 5-pass CCS2 reads were aligned to the HCV1b reference 
(accession no. AB047639.1) using blastn version 2.2.29 with customised parameters (-dust no)26. 
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Based on the blastn results, we found the mismatch rate to be 0.023% (SD = 0.039, 95% CI: 0.023-
0.024) and the error rate to be 0.267% (SD = 0.298, 95% CI: 0.264-0.270) (Supplementary Table S2). 
The sequence data suggested that we obtained more than 7,000 accurate long-reads per sample, 
derived from the region between the NS3 and NS5A genes. 
 
Determination of RAS haplotypes of the HCV genome 
To analyse the dynamics of the drug-resistant viral clones during the DAA treatment in a simple 
manner, we determined the linkage of seven RASs (Q80 and D168 in NS3, and R30, L31, P32, Q54, 
and Y93 in NS5A) from the NS3 to NS5A genes of each viral clone, and reduced the dimensions of 
the haplotype data (Figure 2).  
First, to determine the position of the NS3 and NS5A genes in each clone, we aligned the ≥ 5-pass 
CCS reads to the sequences of the NS3 (3,408 - 5,300) and NS5A genes (6,246 - 6,735) in the HCV 
reference genome (accession no. D90208.1) by blastn version 2.2.29 with customised parameters (-
dust no)26. According to the results from the blastn, each codon from the CCS2 reads that was in one 
of the seven RASs, was extracted. Of the CCS2 reads, those possessing frameshift indels or not mapped 
to NS3 or NS5A were excluded from haplotype determination. Next, to convert the linkage information 
of the seven codon changes to low-dimensional digital data, we encoded the original codon (wild 
codon) as 0, a synonymous codon as 1, and a nonsynonymous codon as 2 (Figure 2). The original 
codons and the synonymous codons for the seven-RAS loci are defined in Supplementary Table S3. 
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After translating each codon to the code, we constructed a 7-digit code for 7-RAS haplotypes by 
combining these codes (Figure 2). Before applying the coding procedure, the total number of HCV 
clones between the NS3-NS5A genes was 187,539, and the average number was as high as 5,358 (SD 
= 3460.05) haplotypes per sample (Table 1). In contrast, after the construction of the 7-digit coded 
haplotypes, the number of the viral haplotypes were summarised to 24 on average (SD = 20.45). 
Consequently, the coding procedure simplified thousands of HCV clone types into fewer than one 
hundred types, using the haplotype code for the 7-RAS loci, making the overall picture of the HCV 
quasispecies in each sample clearer and easier to understand. 
 
Dynamics of the 7-RAS haplotypes between the DAA pre- and post-treatment 
To examine the dynamics of the 7-RAS haplotypes, we listed the haplotype codes at each timepoint 
and compared the relative frequency of the 7-RAS haplotypes between the pre- and post-treatment 
samples of a total of 15 DAA treatments (before and after DCV/ASV in cases #1 - #12, and before and 
after SMV in cases #9, #10 and #12; Supplementary Table S4). Then, to exclude the haplotypes 
derived from artefacts, we set the mismatch rate + 2SD as the threshold (0.103%) and listed the 
haplotype codes with over 0.103% frequency in the samples. In 5 of the 15 paired comparisons (#5-
DCV/ASV-pre/post, #8-DCV/ASV-pre/post, #9-SMV-pre/post, #10-SMV-pre/post and #10-
DCV/ASV-pre/post), the major haplotypes had multiple RASs present when the treatment failed, also 
existing in 0.14-1.26% of the CCS2 reads at pre-treatment. Meanwhile, in the other ten paired 
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comparisons, the major haplotypes only had RASs present when the treatment failed. Of these 5 paired 
comparisons, the dynamics of the haplotypes in the 2 representative cases are demonstrated in Figure 
3 (#5-DSV/ASV-pre/post paired samples and #8-DSV/ASV-pre/post paired samples).  
During the DCV/ASV treatment in case #5 (Figure 3A), the haplotype code “0202012” was the 
ninth most frequent haplotypes in the pre-treatment samples. However, after treatment, haplotype 
“0202012” increased to the most frequent haplotype. Likewise, with the example of case #5 (Figure 
3B), its ninth most frequent haplotype before treatment, “0202022”, became the most frequent 
haplotype after treatment failure, and showed resistance to DCV and ASV due to the nonsynonymous 
changes of NS3-D168, NS5A-L31, and NS5A-Y93. These data suggest that low-abundance multidrug-
resistant viral clones exist before the DAA treatment.  
We also focused on the change in the number of haplotype codes from the pre-treatment of DAAs 
(DCV/ASV and SMV) to relapse (Figure 4A). With DCV/ASV treatment, the number of haplotypes 
significantly decreased by 8.08 (SD = 18.77, 95% CI: 4.5-12.5) from 14.67 (SD = 9.12) with pre-
treatment of DCV/ASV, and to 6.58 (SD = 7.1) at relapse (p = 0.00293). In contrast, comparing the 
means of the nonsynonymous codons of the 7-RAS loci per CCS2 read before and after DSV/ASV 
therapy, the number of nonsynonymous codons significantly increased by 2.14 (SD = 0.96, 95% CI: 
1.35-2.91) from 1.50 (SD = 0.92) at the pre-treatment to 3.64 (SD = 0.75) at treatment failure (p = 
0.0004883) (Figure 4B). With SMV treatment, neither the number of haplotype codes (mean = 4, SD 
= 10.68, 95% CI: -5-19) nor the number of nonsynonymous codons (mean = 0.87, SD = 0.17, 95% 
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CI: 0.63-1.00) showed significant differences, due to the small paired-sample size (Figure 4C and 
4D). 
 Although the coded haplotypes lacked the detailed information of each codon, the comparison of 
haplotype codes during DAA therapy suggests that rare HCV clones with multiple RASs at pre-
treatment might be the cause of relapse as they became the major haplotype after treatment failure. In 
addition, the significant reduction in the number of haplotype codes and the significant gain in the 
nonsynonymous codons at RAS loci at treatment failure, indicates the clonal selection of viruses with 
survival benefit under anti-HCV treatment. 
 
Structural variations detected by SMRT sequencing 
To understand the viral clones at a deeper level, we analysed structural variation in the HCV-RNA 
genome at single-clone resolution. To call candidates with ≥ 30-bp SVs, we executed ngmlr and 
Sniffles for each sample. In all cases, a total of 6,512 CCS2 reads had SVs, corresponding to 2.29% of 
all ≥- 5-pass CCS2 reads. In particular, deletions were detected in 4,393 of CCS2 reads (1.54%), while 
duplications, insertions, inversions, and U-turns (INVDUP) were detected in 220 (0.08%), 61 (0.02%), 
68 (0.02%), and 1,906 reads (0.67%), respectively (Figure 5, Supplementary Table S5). 
We focused on the 10 SVs detected with frequencies of ≥ 1% of the CCS2 reads, and examined the 
changes in their frequencies after the treatment (Supplementary Figure S2, Supplementary Table 
S6). Two examples (SV7 and 10) of the 10 SVs are shown in Figure 6A and 6B, respectively. In the 
11 
 
case of SV7, the CCS2 reads lacked the sequence located at the region between 5,299 - 5,722 on the 
HCV reference genome (accession no. D90208.1), including parts of NS3, NS4A, and NS4B (Figure 
6A). In the validation, two of the Ion Proton reads were aligned to the region the SV occurred in. Also, 
in the case of SV10 (Figure 6B), the CCS2 reads lacked the sequence between the 3,644 - 4,763, 
including part of NS3. In the validation, 925 of the Ion Proton reads were aligned to the region the SV 
occurred in. Of these 10 SVs, six (SV1, 2, 4, 5, 6, and 8) existed at the pre-treatment and vanished 
after the treatment. In contrast, two SVs (SV3 and 7) appeared for the first time after treatment failure. 
The remaining SV (SV9) was detected throughout the treatment period. 
As shown in these SVs, we identified HCV clones harbouring simple SVs and their various 
dynamics. 
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Discussion 
To completely eradicate HCV, a deep understanding of the genetic background behind multidrug-
resistant HCV clones is important. However, as second-generation sequencers generate up to 2 × 300 
bp paired-end reads, deep sequencing with these technologies cannot detect the linkage of multiple 
RASs between NS3 and NS5B genes and elucidate multi-drug resistance at single clone level. In the 
current study, we have established a methodology to evaluate viral quasispecies by linkage information 
of multiple RASs from NS3 to NS5A genes, on every viral clone in the sera, using recently developed 
SMRT sequencing technologies, which can generate extremely long sequence reads. 
We have previously applied SMRT sequencing to evaluate viral quasispecies and the generation 
process of multi-drug resistant viral clones at the single viral clone level25. The amount of sequencing 
data, however, was extremely large, and the methodology required to conduct the subsequent 
phylogenetic analysis extremely complicated, especially when considering a common use-case of this 
technology: as a part of bed-side examinations in a clinical setting. In contrast, in the current study, we 
converted the complicated information of multiple codon changes during treatment into a simple 
seven-digit code, associated with drug resistance in each sequence read. Using this simplified 
methodology, the large quantity of data from the SMRT sequencing was aggregated into a simpler 
form that enabled easier evaluation of the complicated viral heterogeneity of HCV and its dynamics 
during DAA treatment.    
Another advantage of the current study is the establishment of long-read deep sequencing for a 
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viral genome, using the CCS2 algorithm for error correction. In our previous report on HCV analysis 
using SMRT sequencing, we used 10-pass CCS reads to evaluate only accurate sequence reads, 
resulting in approximately 200-500 clones, with 99.65% accuracy per sample, eligible for analysis. 
These methods could miss rare variants in each serum sample. To improve this, in the current study, 
we used CCS2 reads generated by the new error correction algorithms, which are more accurate than 
the previously used CCS reads, and a total of 187,539 CCS2 reads in the 35 samples could be analysed 
with 99.73% accuracy. The 5,358 HCV clones found per sample indicate that mutations constantly 
occur in the HCV genome, resulting in the amplification of extremely diverse HCV clones in vivo. In 
addition, comparing the long-read deep sequencing data between the pre- and post-treatments, we 
found that the major 7-RAS haplotypes with multi-drug resistance in post-treatment existed at low 
abundance during pre-treatment. This highlights how our strategy, with long-read deep sequencing and 
encoding of viral haplotypes, could be utilised to analyse the dynamics of multi-drug resistant viral 
clones.  
Taking advantage of long-read sequencing methodology, we also identified several SVs including 
long deletions or U-turns (INVDUP) on the HCV RNA genome and compared the frequencies of the 
SVs during the treatments. In addition, to the best of our knowledge, this study is the first investigation 
of the dynamics of HCV mutants harbouring SVs during treatment, where dynamics include the 
appearance and disappearance of HCVs at relapse. Among the SVs reported in the HCV genome, 
defective HCV clones lacking a subset of structural proteins are occasionally detected in some patients’ 
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sera27. We should consider that reports of defective HCV arise from the potential artefacts generated 
during the RT-PCR process. However, if the defective HCV indeed exists in patients’ sera, they may 
be amplified in the patients’ hepatocytes, not by their NS proteins but rather using the proteins of co-
infecting full-length HCV clones. It remains unclear how these incomplete genomes are formed and 
maintained and whether they are associated with drug resistance or the escape from host immunity. In 
addition, recombinant HCV clones with different genotypes have also been reported28, although it is 
not clear how these viral clones were generated. 
One of the limitations of our study is its small sample size. We analysed only three paired samples 
of SMV treatment and did not study the dynamics of 7-RAS haplotypes during SMV treatment. Also, 
although we evaluated the dynamics of the 7-RAS haplotypes in HCV samples, we could not find how 
the distribution of these haplotypes influences HCV genome replication and treatment outcome. To 
investigate the relationship between HCV quasispecies and these outcomes, a larger sample size than 
that of the current study would be required. 
The second limitation arises from the elimination of detailed nucleotide information, which might 
be associated with treatment efficacy, in exchange for simplification of the haplotype code. However, 
the simple digital codes can be generated from any locus of interest to the investigators. Thus, 
according to the study design, the essential loci may be included in the digital haplotype code and their 
dynamics can easily be analysed. Although we suggest that HCV clones with multiple RASs may in 
some cases become the most frequent clones at treatment failure, the possibility cannot be excluded 
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that selection was due to other mutations than those of the 7-RAS loci used for the generation of the 
haplotype code. Moreover, for a deeper understanding of their dynamics, NS5B and other genes should 
be analysed using whole-genome SMRT sequencing. 
The last limitation of this study is that we cannot show how SVs and the dynamics described in 
this study affect the biological features of HCV and affected patients. To elucidate the function of SVs 
in the HCV genome, further analysis with a greatly increased HCV sample size is required. 
In conclusion, we have established an encoding methodology to evaluate the dynamics of drug-
resistant 7-RAS haplotypes. Coding each RAS greatly simplified the interpretation and analysis of 
viral haplotypes. In addition, taking advantage of long-read sequencing, we identified several SVs and 
described their dynamics in HCV genomes, although their virological significance should be further 
investigated in the future. Importantly, using our methodology, which simplifies the unwieldy data that 
is the output of third-generation sequencers into simple digital code data, SMRT sequencing could be 
applied to large-scale investigations with much larger sample sizes. Moreover, it is ideal to be applied 
to other viruses like hepatitis B viruses (which cannot be completely eliminated from the host) and 
human immunodeficiency viruses (whose multi-drug resistant variants are currently a clinically 
significant issue).  
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Materials and Methods 
Patients and sample collection 
Patients with genotype 1b HCV infections, who were assigned to receive DCV/ASV therapy at 
Kyoto University, were enrolled in this study from September 2014 to December 2016 (Figure 1). 
This manuscript includes reanalysis of clinical samples and sequence data from a previously published 
article25. Of a total of 112 patients who received DCV/ASV treatment, 18 failed to display SVR. We 
performed reverse transcription polymerase chain reaction (RT-PCR) on 16 samples, as described 
below. The samples of two further patients were not available for RT-PCR. Following the RT-PCR 
procedure, the samples from 12 patients underwent single-molecule real-time (SMRT) sequencing as 
described in the following section. 
As a result, 35 HCV-RNA samples from 12 patients who experienced treatment failure with DAA 
were analysed in this study. Sixteen samples from eight patients (Cases #1 - #8) were paired samples 
before and after receiving NS5A inhibitor daclatasvir and NS3 protease inhibitor asunaprevir 
(DCV/ASV) combination therapy (Figure 1). Nineteen samples from four patients (Cases #9 - #12), 
who received treatment with the NS3 inhibitor simeprevir (SMV) combined with peginterferon and 
ribavirin therapy, DCV/ASV treatment and the NS5B polymerase inhibitor sofosbuvir and NS5A 
inhibitor ledipasvir (SOF/LDV) combination therapy, were sequentially collected: (1) before SMV 
treatment; (2) at relapse after SMV treatment; (3) before DCV/ASV treatment; (3) at relapse after 
DCV/ASV treatment; and/or (4) before SOF/LDV treatment. All 4 patients (Case #9 - #12) finally 
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achieved SVR after SOF/LDV therapy, and thus there were no serum samples to analyse afterwards. 
The patients’ characteristics and sample information are summarised in Table 1 and Supplementary 
Table S7. 
Total-RNA was extracted from serum using the QIAquick Viral Mini kit (Qiagen, Valencia, CA, 
USA) following the manufacturer’s protocol. Written informed consent was obtained from each patient 
prior to DAA therapy. All protocols were approved by the ethics committee of Kyoto University and 
Chiba University. This study protocol complied with all provisions of the Declaration of Helsinki. 
 
Single-molecule real-time (SMRT) sequencing 
We amplified 3120-bp HCV sequences between the NS3 and NS5A genes by using the PrimeScript 
One Step RT-PCR kit (Takara Bio, Shiga, Japan) and PrimeSTAR HS kit (Takara) according to the 
manufacturer’s protocol (Figure 1, Supplementary Materials). Also, we prepared two samples of 
HCV-containing plasmids for control experiments and amplified the NS3-to-NS5A region with the 
above method. The primers for RT-PCR are shown in Supplementary Table S8. The PacBio DNA 
library was constructed from purified DNA product (5 µg) using a DNA Template Prep Kit 3.0 (Pacific 
Biosciences, Menlo Park, CA, USA) according to the PacBio standard template prep protocol (Pacific 
Biosciences)29. The DNA library was sequenced using PacBio RS II following the protocol from 
Pacific Biosciences. We used P6C4 polymerase for the sequencing reaction and 6-h movie windows 
for signal detection. 
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Circular consensus sequencing 
To improve the accuracy of the sequenced raw reads, fasta/fastq files of the Circular Consensus 
Sequence 2 (CCS2) reads were generated using pbsmrtpipe 0.44.8 with CCS2 default settings (Figure 
1). After obtaining the CCS2 reads, we extracted the ≥ 5-pass CCS2 reads, using perl version 5.18.2. 
To extract the ≥ 5-pass CCS2 reads with nested PCR primer sequences, the CCS2 reads were mapped 
to the primer sequences by blastn version 2.2.29 with specific parameters (-word_size 4 -reward 1 -
penalty -3)26. Based on the blastn results, we extracted the CCS2 reads aligned to the primer on each 
end with ≥ 85% of identity. To examine the coverage of these CCS2 reads, we used BLASR version 
1.3.1 for mapping CCS2 reads to the HCV reference genome, and GATK version 3.3.2 for calculating 
the coverage of the CCS2 reads with parameter “-T DepthOfCoverage -DBQ 030,31.” The sequence 
data for the HCV clones with novel sequences identified in this study have been submitted to the 
DDBJ/EMBL/GenBank databases under accession number DRA00913225. 
 
Determination of structural variations 
For the detection of the structural variations of the HCV-RNA genome, all ≥ 5-pass CCS2 reads 
were aligned to the HCV reference genome sequence (accession no. D90208.1) using ngmlr version 
0.2.6 with the default parameters32. Based on the data of the mapped sequences, structural variations 
(SVs) were called by Sniffles version 1.0.11 with customised parameters (-t 36 -s 1 -n -1 -r 500 -d 100 
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--cluster --report_seq --ccs_reads)32. Sniffles detected ≥ 30-bp SVs and defined the types of SVs as 
described in Figure 6. We evaluated these SVs according to Sniffles’ vcf/bedpe output. To exclude 
artefacts, SVs identified in only a single CCS2 read and multiple SVs in a single read were filtered out. 
For the visualisation of the SVs, we used nucmer (MUMmer4 package) with adjusted parameters “-
maxmatch -l 10” and mummerplot (MUMmer4 package) with default parameters33. 
 The detected SVs were validated by the reads generated from Ion Proton Sequencer (ThermoFisher 
Scientific, Waltham, MA, USA)25. We generated the libraries from 100 ng of genomic DNA and an 
Ion Xpress Plus Fragment Library Kit including the Ion Shear Plus Reagents Kit. The amplicons 
described in the section of SMRT sequencing were ligated to the Ion Xpress Barcode Adapters. 
TapeStation with a DNA 1000 kit (Agilent, Santa Clara, CA, USA) was used for the visualisation of 
the size range. We also used Ion Library Taqman Quantitation Kit to identify the library concentration. 
Following the Ion PI Template OT2 200 Kit User Guide, the diluted library was utilised as a template 
for clonal amplification on Ion Sphere particles at the emulsion PCR stage. We performed the 
sequencing over 400 cycles with the Ion PI Sequencing 200 Kit v3 on an Ion PI Chip (Life 
Technologies).  
 We aligned Ion Proton reads to SV regions in the CCS2 reads by blastn version 2.2.2926. If the 
multiple Ion Proton reads were aligned to the SV regions with > 95% similarity, we considered that 
the SV existed in the HCV clones. 
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Statistical analysis  
To compare the number of haplotypes and the number of nonsynonymous codons per HCV clone 
between the samples prior to DAA treatment and at treatment failure, continuous variables were 
analysed using the Wilcoxon signed-rank test. Data were analysed using R ver.3.3.2. Two-tailed 
probability values of p < 0.05 were considered significant. 
 
Data Availability 
The sequence reads are available in the DNA Data Bank of Japan Sequence Read Archive under 
accession number DRA009132, 
[https://trace.ddbj.nig.ac.jp/DRASearch/submission?acc=DRA009132]. 
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Table 1. Sample information. 
Case Sample Timepoint Description HCV 
RNAa 
serum 
ALTb 
# of HCV  
clonesc 
# of haplotype 
codes 
#1 #1-DCV/ASV-pre 1 before DCV/ASV 6.6 43 337 6 
 
#1-DCV/ASV-post 2 after DCV/ASV 5.2 28 6,949 13 
#2 #2-DCV/ASV-pre 1 before DCV/ASV 6.6 33 8,599 52 
 
#2-DCV/ASV-post 2 after DCV/ASV 5 32 257 5 
#3 #3-DCV/ASV-pre 1 before DCV/ASV 5.5 29 5,583 23 
 
#3-DCV/ASV-post 2 after DCV/ASV 4.8 26 142 5 
#4 #4-DCV/ASV-pre 1 before DCV/ASV 5.4 42 1,469 21 
 
#4-DCV/ASV-post 2 after DCV/ASV 5.2 25 12,525 11 
#5 #5-DCV/ASV-pre 1 before DCV/ASV 7.1 13 10,854 32 
 
#5-DCV/ASV-post 2 after DCV/ASV 6.2 14 7,743 12 
#6 #6-DCV/ASV-pre 1 before DCV/ASV 6.1 30 1,850 26 
 
#6-DCV/ASV-post 2 after DCV/ASV 5.8 24 4,117 8 
#7 #7-DCV/ASV-pre 1 before DCV/ASV 6.2 65 2,273 49 
 
#7-DCV/ASV-post 2 after DCV/ASV 5.5 31 5,429 11 
#8 #8-DCV/ASV-pre 1 before DCV/ASV 6.3 81 3,954 39 
 
#8-DCV/ASV-post 2 after DCV/ASV 3.8 20 340 6 
#9 #9-SMV-pre 1 before SMV/PegIFN/RBV 7.8 119 6,257 15 
 
#9-SMV-post 2 after SMV/PegIFN/RBV 4.5 9 3,678 10 
 
#9-DCV/ASV-pre 3 before DCV/ASV 7.2 76 5,454 35 
 
#9-DCV/ASV-post 4 after DCV/ASV 4.7 21 9,917 12 
 
#9-SOF/LDV-pre 5 before SOF/LDV 7.8< 136 8,556 24 
#10 #10-SMV-pre 1 before SMV/PegIFN/RBV 6.8 55 6,923 17 
 
#10-SMV-post 2 after SMV/PegIFN/RBV 6.6 28 7,065 18 
 
#10-DCV/ASV-pre 3 before DCV/ASV 6.2 81 7,184 13 
 
#10-DCV/ASV-post 4 after DCV/ASV 3.5 16 9,942 12 
 
#10-SOF/LDV-pre 5 before SOF/LDV 5.9 52 11,858 12 
#11 #11-SMV-pre 1 before SMV/PegIFN/RBV 6.9 66 2,763 10 
 
#11-DCV/ASV-pre 2 before DCV/ASV 5.7 18 6,285 15 
 
#11-DCV/ASV-post 3 after DCV/ASV 7.2 89 1,645 6 
 
#11-SOF/LDV-pre 4 before SOF/LDV 6.3 66 1,499 53 
#12 #12-SMV-pre 1 before SMV/PegIFN/RBV 7.6 38 7,235 25 
 
#12-SMV-post 2 after SMV/PegIFN/RBV 7.6 31 7,273 73 
 
#12-DCV/ASV-pre 3 before DCV/ASV 7.2 50 6,506 92 
 
#12-DCV/ASV-post 4 after DCV/ASV 7.4 17 628 30 
 
#12-SOF/LDV-pre 5 before SOF/LDV 7 31 4,450 58 
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DCV, daclatasvir; ASV, asunaprevir; SMV, simeprevir; PegIFN, peginterferon; RBV, ribavirin; SOF, 
sofosbuvir; LDV, ledipasvir; a logIU/mL; b U/L; c The number of CCS2 reads except for the same 
sequences as other reads in comparing CCS2 reads in sample each other by blastn. 
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Figure 1. Sample collection and single-molecule real-time sequencing workflow. 
This flow consisted of sample collection, reverse transcription polymerase chain reaction (RT-PCR), 
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single-molecule real-time (SMRT) sequencing, and Circular Consensus Sequencing2 (CCS2). For 
cases #1 - #8, the samples were extracted prior to treatment and after treatment failure of the 
daclatasvir + asunaprevir (DCV/ASV). For cases #9 - #12, the samples were extracted prior to 
treatment with simeprevir (SMV) combined with peginterferon and ribavirin, DCV/ASV and 
sofosbuvir + ledipasvir (SOF/LDV), and after the treatment failure of the SMV and DCV/ASV. RT-
PCR amplified the NS3-NS5A gene regions of the cDNA transcribed from HCV-RNA. For SMRT 
sequencing, we constructed the library by binding the adapters to the cDNA by ligation. The library 
was sequenced with PacBio RS II. While the sequenced raw reads included sequencing errors, 
CCS2, the error correction algorithm, generated highly accurate reads by correcting the errors with 
the raw reads repetitively sequenced in single the molecules.  
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Figure 2. The flow of determining haplotype codes. 
The method for determining the haplotype code consists of 4 steps: (1) mapping CCS2 reads to the 
NS3/NS5A gene sequences using blastn, (2) extracting each codon from the 7 RAV-sites in the CCS2 
reads, based on the blastn results, converting each codon of the 7 RAV-sites to three numbers (0, 1, 
and 2), and combining all codons to make a haplotype. The figure shows the example of the steps, 
from aligning the CCS2 reads to constructing a haplotype.  
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Figure 3. Dynamics of haplotype codes before treatment and after treatment failure. 
(A). Comparison of the haplotypes between #5-DCV/ASV-pre and #5-DCV/ASV-post. Before 
therapy, “0202012”, resistant to both the NS3 inhibitor and NS5A inhibitor, existed at a frequency of 
0.32% (left table). In contrast, the relative abundance of “0202012” increased to 98.86%, with 
treatment failure (right table). The % in each table represents the percentage for the number of the 
CCS2 reads in the sample. (B). Comparison of haplotypes between #8-DCV/ASV-pre and #8-
DCV/ASV-post. Although haplotype “0202022” was 1.26% and the minor haplotype at pre-
treatment, this haplotype was 82.65%, and the major haplotype at treatment failure. The % in each 
table represents the percentage for the number of the CCS2 reads in the sample.  
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Figure 4. Differences in the haplotype profiles, both pre- and post-treatment on 
daclatasvir/asunaprevir and simeprevir. 
(A). The graph demonstrates the differences in the number of haplotype codes between pre-and post-
treatment with daclatasvir/asunaprevir (DCV/ASV). The x-axis represents the timepoint of the sera 
collection, and the y-axis represents the number of haplotypes. The Wilcoxon signed-rank test was 
used for the statistical examination of the difference between the number of haplotype codes. (B). 
The graph demonstrates the difference in the number of nonsynonymous codons per clone from pre-
treatment of DCV/ASV to post-treatment. The x-axis represents the timepoint of the sera collection 
and the y-axis represents the mean number of nonsynonymous codons on the 7-RAS loci, per HCV 
clone. The Wilcoxon signed-rank test was used for the statistical examination of the differences 
between the number of nonsynonymous codons. (C). The graph demonstrates the differences in the 
number of haplotype codes between pre-and post-treatment with simeprevir (DCV/ASV). The x-axis 
represents the timepoint of the sera collection, and the y-axis represents the number of haplotypes. 
(D). The graph demonstrates the difference in the number of nonsynonymous codons per clone from 
the pre-treatment of SMV to the post-treatment. The x-axis represents the timepoint of the sera 
collection and the y-axis represents the mean number of nonsynonymous codons on the 7 RAS loci, 
per HCV clone.  
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Figure 5. The definition of structural variations (SVs) by Sniffles. 
The figure is adapted from the article of Sniffles32 with focus on the relationship between the 
reference genome sequence and the sample genome sequence with each SV32. Sniffles is able to 
detect 8 types of SVs, such as deletions, duplications, insertions, inversion, translocation, nested 
variation (inversion+deletion and duplication+inversion), and U-Turns (INVDUP). The red regions 
indicate regions where an SV occurs. The red points stand for the breakpoint of deletions.  
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Figure 6. The detection of the genome structure harbouring SVs between the NS3 and NS5A 
gene regions. 
The mapping software ngmlr version 0.2.6 aligned ≥ 5-pass CCS reads to the HCV genome, and the 
structural variation (SV)-calling software, Sniffles, detected ≥ 30-bp SVs. The figure demonstrates 
that two deletions exist at a relative abundance of ≥ 1% in the samples. In each panel, the upper 
schema shows the HCV genome with SV from the NS3 to the NS5A gene regions. The red symbols 
stand for the region that the SV in question occurred in. In particular, the inverted letters in the 
schema mean “inversion,” and the boxes with dash lines mean “deletion.” The genome positions 
described here are based on the HCV reference sequence (accession no. D90208.1). The lower image 
demonstrates the alignment of the representative reads supporting the SVs by the MUMmer program. 
The x-axis shows the position of the HCV reference genome. The Y-axis shows the position of the 
reads harbouring SVs. The purple solid line shows the alignment for an HCV reference genome 
without SVs. The blue solid line shows the inverted alignment for an HCV reference genome. The 
red point shows the SV region on the CCS2 read, which was used for SV validation. (A). In sample 
#12-SMV-post, a 423-bp deletion was detected. (B). In #12-SOF/LDV-pre, 1,119-bp deletion was 
clonally detected.  
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Supplementary Table S1. The summary of SMRT sequencing result. 
sample# 
# of total 
raw read 
total raw read 
sizea 
# of ≥5pass 
CCS2 read 
≥5pass CCS2 
read sizea 
meanQV 
# of filtered ≥
5pass CCS2 read 
%b 
filtered ≥ 5pass 
CCS2 read sizea 
%c meanQV 
#1-DCV/ASV-pre 510,244 1,099,815,353 10,996 27,109,353 73.93 337 3.06 1,061,429 3.92 68.05 
#1-DCV/ASV-post 453,631 1,252,188,326 7,836 24,305,342 69.31 6,949 88.68 21,800,435 89.69 69.91 
#2-DCV/ASV-pre 330,630 907,896,832 13,822 43,037,686 70.66 8,599 62.21 26,996,129 62.73 71.76 
#2-DCV/ASV-post 7,696 20,534,111 295 919,761 72.13 257 87.12 805,299 87.56 73.25 
#3-DCV/ASV-pre 268,740 632,506,124 6,759 21,210,195 72.06 5,583 82.6 17,515,217 82.58 73.08 
#3-DCV/ASV-post 328,445 853,546,231 11,109 34,680,565 73.66 142 1.28 451,732 1.3 69.72 
#4-DCV/ASV-pre 77,666 187,282,071 2,269 6,913,683 68.76 1,469 64.74 4,623,429 66.87 69.19 
#4-DCV/ASV-post 426,279 1,094,840,677 14,077 43,722,095 73.14 12,525 88.97 39,250,263 89.77 73.86 
#5-DCV/ASV-pre 646,065 1,307,869,632 17,352 44,196,185 71.66 10,854 62.55 34,057,679 77.06 71.02 
#5-DCV/ASV-post 232,614 597,440,610 8,669 26,829,682 72.92 7,743 89.32 24,273,370 90.47 73.48 
#6-DCV/ASV-pre 213,145 479,267,374 2,308 6,982,735 68.89 1,850 80.16 5,680,635 81.35 69.22 
#6-DCV/ASV-post 254,853 625,695,121 4,443 13,837,929 72.67 4,127 92.89 12,922,292 93.38 73.09 
#7-DCV/ASV-pre 177,665 516,158,975 4,035 12,395,553 55.4 2,273 56.33 7,146,460 57.65 55.9 
#7-DCV/ASV-post 170,894 491,511,378 6,058 18,960,068 71.89 5,430 89.63 16,998,203 89.65 72.33 
#8-DCV/ASV-pre 219,126 617,978,886 5,450 16,674,905 68.35 3,954 72.55 12,390,341 74.31 68.8 
#8-DCV/ASV-post 34,534 75,052,620 542 1,519,575 68.11 340 62.73 1,066,172 70.16 67.81 
#9-SMV-pre 311,545 886,532,826 7,099 23,078,811 60.13 6,258 88.15 20,440,202 88.57 60.7 
#9-SMV-post 248,611 726,220,090 4,248 13,897,256 56.8 3,678 86.58 12,030,459 86.57 57.35 
#9-DCV/ASV-pre 262,738 723,050,281 7,208 23,495,909 63.61 5,454 75.67 17,819,855 75.84 64.47 
#9-DCV/ASV-post 293,763 859,749,387 10,788 35,220,730 68.39 9,920 91.95 32,388,684 91.96 69.02 
#9-SOF/LDV-pre 390,977 1,071,206,956 10,012 32,615,370 67.27 8,556 85.46 27,947,074 85.69 68.07 
#10-SMV-pre 197,605 580,672,538 7,803 25,510,987 60.02 6,923 88.72 22,639,211 88.74 60.63 
#10-SMV-post 197,856 582,511,219 8,610 28,115,343 63.35 7,065 82.06 23,099,698 82.16 64.09 
36 
 
Supplementary Table S1. The summary of SMRT sequencing result (continued). 
sample# 
# of total  
raw read 
total raw  
read sizea 
# of ≥5pass  
CCS2 read 
≥5pass CCS2 
 read sizea meanQV 
# of filtered  
≥5pass CCS2 read %b 
filtered ≥5pass  
CCS2 read sizea %c meanQV 
#10-DCV/ASV-pre 173,857 519,100,535 7,775 25,390,719 66.88 7,185 92.41 23,468,397 92.43 67.46 
#10-DCV/ASV-post 268,765 816,485,660 11,049 36,106,581 69.53 9,944 90 32,489,642 89.98 70.33 
#10-SOF/LDV-pre 342,008 994,791,858 12,643 41,281,483 70.7 11,874 93.92 38,767,881 93.91 71.28 
#11-SMV-pre 164,334 453,300,261 3,400 11,041,519 56.73 2,763 81.26 9,039,580 81.87 56.93 
#11-DCV/ASV-pre 163,998 483,781,758 6,686 21,812,645 71.65 6,289 94.06 20,537,627 94.15 72.16 
#11-DCV/ASV-post 179,587 540,275,184 7,831 25,521,533 68.29 1,645 21.01 5,362,915 21.01 68.53 
#11-SOF/LDV-pre 234,447 718,137,360 9,074 29,577,245 70.85 1,499 16.52 4,902,236 16.57 71.09 
#12-SMV-pre 267,723 790,852,567 9,267 30,188,553 60.01 7,235 78.07 23,666,941 78.4 60.72 
#12-SMV-post 344,192 1,016,227,005 10,158 32,652,436 62.41 7,273 71.6 23,558,707 72.15 63.46 
#12-DCV/ASV-pre 316,154 878,879,354 10,694 31,924,336 65.32 6,512 60.89 20,355,835 63.76 65.72 
#12-DCV/ASV-post 323,262 962,701,937 13,686 44,444,303 70.31 628 4.59 1,985,309 4.47 69.94 
#12-SOF/LDV-pre 309,111 887,468,206 10,514 33,751,999 71.48 4,450 42.32 14,541,710 43.08 72.38 
CCS2, circular consensus sequencing 2; QV, quality value; SMV, simeprevir; DCV, daclatasvir; ASV, asunaprevir; SOF, sofosbuvir; LDV, ledipasvir; abp; 
bpercentage for the total number of the ≥5-pass CCS2 reads in the sample; cpercentage for the total size of the ≥5-pass CCS2 reads in the sample.  
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Supplementary Table S2. The error rate of HCV sequencing calculated from HCV-containing 
plasmids. 
Valuables   
# of ≥5-pass CCS2 reads 38,364 
total ≥5-pass CCS2 reads size (bp) 101,683,536 
average of match bases (bp) 2640.57 
average of mismatch bases (bp) 0.62 
average of gap open bases (bp) 7.26 
mismatch rate (%) 0.023 
error rate (%) 0.267 
CCS2, circular consensus sequencing 2  
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Supplementary Table S3. The codon information of 7 RASs. 
RAS locus 
start 
positiona 
end 
positiona 
wild 
codon 
synonymous codon 
NS3-Q80 3,645 3,647 CAG CAA 
NS3-D168 3,909 3,911 GAC GAT 
NS5A-R30 6,333 6,335 CGG CGA, CGC, CGT 
NS5A-L31 6,336 6,338 TTA TTG, CTT, CTC, CTA, CTG 
NS5A-P32 6,339 6,341 CCG CCA, CCT, CCC 
NS5A-Q54 6,405 6,407 CAA CAG 
NS5A-Y93 6,522 6,524 TAC TAT 
aBase position based on HCV reference genome (accession no. D90208.1). 
Nonsynonymous codon is defined as the codon except wild codon and synonymous codon. 
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Supplementary Table S4. All of the coded haplotypes in each sample. 
sample# #1-DCV/ASV-pre     #1-DCV/ASV-post     
ranka haplotype 
# of 
CCS2 
%b haplotype 
# of 
CCS2 
%b 
1 0012020 269 79.82 0212022 6,207 89.32 
2 0002020 63 18.69 0012022 667 9.6 
3 0212020 2 0.59 2212022 24 0.35 
4 2012020 1 0.3 0212222 23 0.33 
5 0202020 1 0.3 0222022 8 0.12 
6 0022020 1 0.3    
CCS2, circular consensus sequencing 2; SVs, structural variations; SMV, simeprevir; DCV, daclatasvir; 
ASV, asunaprevir; SOF, sofosbuvir; LDV, ledipasvir; asorting by frequency of each haplotype in descending 
order; bpercentage for the total number of the filtered ≥5-pass CCS2 reads in the sample. 
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Supplementary Table S4. All of the coded haplotypes in each sample (continued). 
sample# #2-DCV/ASV-pre     #2-DCV/ASV-post     
ranka haplotype 
# of 
CCS2 
%b haplotype 
# of 
CCS2 
%b 
1 0001000 3,647 42.41 0202012 253 98.44 
2 1001000 2,030 23.61 2202012 1 0.39 
3 0000000 1,240 14.42 1202012 1 0.39 
4 0001002 968 11.26 0222012 1 0.39 
5 1000000 237 2.76 0202212 1 0.39 
6 1001002 210 2.44    
7 0000002 111 1.29    
8 1000002 21 0.24    
9 2001000 16 0.19    
10 0201000 12 0.14    
11 0002000 12 0.14    
12 1002000 11 0.13    
13 0001200 11 0.13    
CCS2, circular consensus sequencing 2; SVs, structural variations; SMV, simeprevir; DCV, daclatasvir; 
ASV, asunaprevir; SOF, sofosbuvir; LDV, ledipasvir; asorting by frequency of each haplotype in descending 
order; bpercentage for the total number of the filtered ≥5-pass CCS2 reads in the sample. 
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Supplementary Table S4. All of the coded haplotypes in each sample (continued). 
sample# #3-DCV/ASV-pre     #3-DCV/ASV-post     
ranka haplotype 
# of 
CCS2 
%b haplotype 
# of 
CCS2 
%b 
1 2201010 5,311 95.13 2202022 132 92.96 
2 2101010 87 1.56 2202020 7 4.93 
3 1201010 71 1.27 2202222 1 0.7 
4 1101010 26 0.47 2202220 1 0.7 
5 2201020 15 0.27 2202122 1 0.7 
6 2201012 11 0.2    
7 2201210 10 0.18    
8 2201110 9 0.16    
9 2211010 8 0.14    
10 2200010 8 0.14    
11 2201000 6 0.11    
CCS2, circular consensus sequencing 2; SVs, structural variations; SMV, simeprevir; DCV, daclatasvir; 
ASV, asunaprevir; SOF, sofosbuvir; LDV, ledipasvir; asorting by frequency of each haplotype in descending 
order; bpercentage for the total number of the filtered ≥5-pass CCS2 reads in the sample. 
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Supplementary Table S4. All of the coded haplotypes in each sample (continued). 
sample# #4-DCV/ASV-pre     #4-DCV/ASV-post     
ranka haplotype 
# of 
CCS2 
%b haplotype 
# of 
CCS2 
%b 
1 0201110 1,230 83.73 2222112 12,340 98.52 
2 0201111 98 6.67 2222012 76 0.61 
3 0202110 81 5.51 2222122 43 0.34 
4 0201112 13 0.88 2222212 36 0.29 
5 0201010 9 0.61    
6 0201120 6 0.41    
7 2201110 4 0.27    
8 0202010 4 0.27    
9 0201011 4 0.27    
10 0221110 3 0.2    
11 0211110 3 0.2    
12 2201111 2 0.14    
13 0202210 2 0.14    
14 0202111 2 0.14    
15 0201210 2 0.14    
CCS2, circular consensus sequencing 2; SVs, structural variations; SMV, simeprevir; DCV, daclatasvir; 
ASV, asunaprevir; SOF, sofosbuvir; LDV, ledipasvir; asorting by frequency of each haplotype in descending 
order; bpercentage for the total number of the filtered ≥5-pass CCS2 reads in the sample. 
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Supplementary Table S4. All of the coded haplotypes in each sample (continued). 
sample# #5-DCV/ASV-pre     #5-DCV/ASV-post     
ranka haplotype 
# of 
CCS2 
%b haplotype 
# of 
CCS2 
%b 
1 0002012 9,992 92.06 0202012 7,655 98.86 
2 1002012 204 1.88 0202022 27 0.35 
3 0002010 143 1.32 0202212 19 0.25 
4 0010010 110 1.01 2202012 15 0.19 
5 0010012 88 0.81    
6 0002022 47 0.43    
7 2002012 43 0.4    
8 1010010 38 0.35    
9 0202012 35 0.32    
10 0102012 25 0.23    
11 0012012 22 0.2    
12 0002212 22 0.2    
13 0022012 19 0.18    
14 0002112 13 0.12    
15 1010012 12 0.11    
CCS2, circular consensus sequencing 2; SVs, structural variations; SMV, simeprevir; DCV, daclatasvir; 
ASV, asunaprevir; SOF, sofosbuvir; LDV, ledipasvir; asorting by frequency of each haplotype in descending 
order; bpercentage for the total number of the filtered ≥5-pass CCS2 reads in the sample. 
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Supplementary Table S4. All of the coded haplotypes in each sample (continued). 
sample# #6-DCV/ASV-pre     #6-DCV/ASV-post     
ranka haplotype 
# of 
CCS2 
%b haplotype 
# of 
CCS2 
%b 
1 0010020 1,137 61.46 1212022 4,103 99.42 
2 0011120 389 21.03 0212022 7 0.17 
3 0011020 204 11.03 1212020 6 0.15 
4 0010120 67 3.62    
5 2010020 6 0.32    
6 0010021 6 0.32    
7 1010020 5 0.27    
8 0000020 5 0.27    
9 0012220 4 0.22    
10 1011120 3 0.16    
11 0210020 3 0.16    
12 0012020 3 0.16    
13 0012120 2 0.11    
14 0011220 2 0.11    
15 0011122 2 0.11    
16 0010022 2 0.11    
CCS2, circular consensus sequencing 2; SVs, structural variations; SMV, simeprevir; DCV, daclatasvir; 
ASV, asunaprevir; SOF, sofosbuvir; LDV, ledipasvir; asorting by frequency of each haplotype in descending 
order; bpercentage for the total number of the filtered ≥5-pass CCS2 reads in the sample. 
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Supplementary Table S4. All of the coded haplotypes in each sample (continued). 
sample# #7-DCV/ASV-pre     #7-DCV/ASV-post     
ranka haplotype 
# of 
CCS2 
%b haplotype 
# of 
CCS2 
%b 
1 1001100 1,293 56.89 1202002 5,051 93.02 
2 1001000 387 17.03 0202002 340 6.26 
3 1011000 152 6.69 1202202 16 0.29 
4 1001002 143 6.29 2202002 7 0.13 
5 1001020 39 1.72    
6 1001102 37 1.63    
7 1101100 32 1.41    
8 1011100 27 1.19    
9 1001010 21 0.92    
10 1000100 19 0.84    
11 1000000 14 0.62    
12 1002000 13 0.57    
13 1201100 11 0.48    
14 1011002 7 0.31    
15 1001120 7 0.31    
16 1012000 6 0.26    
17 1001200 6 0.26    
18 1000102 5 0.22    
19 2001100 4 0.18    
20 1101002 4 0.18    
21 1101000 4 0.18    
22 1002002 4 0.18    
23 1201000 3 0.13    
24 1111000 3 0.13    
25 1012002 3 0.13    
CCS2, circular consensus sequencing 2; SVs, structural variations; SMV, simeprevir; DCV, daclatasvir; 
ASV, asunaprevir; SOF, sofosbuvir; LDV, ledipasvir; asorting by frequency of each haplotype in descending 
order; bpercentage for the total number of the filtered ≥5-pass CCS2 reads in the sample. 
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Supplementary Table S4. All of the coded haplotypes in each sample (continued). 
sample# #8-DCV/ASV-pre     #8-DCV/ASV-post     
ranka haplotype 
# of 
CCS2 
%b haplotype 
# of 
CCS2 
%b 
1 1202020 2,365 59.81 0202022 281 82.65 
2 0201022 461 11.66 1202022 53 15.59 
3 1002020 319 8.07 2202022 3 0.88 
4 0202020 252 6.37 1222002 1 0.29 
5 1201022 155 3.92 0222022 1 0.29 
6 1202022 67 1.69 0202222 1 0.29 
7 0201020 67 1.69    
8 1201020 59 1.49    
9 0202022 50 1.26    
10 1212020 25 0.63    
11 1202120 25 0.63    
12 1202000 17 0.43    
13 1012020 13 0.33    
14 2202020 10 0.25    
15 1202220 10 0.25    
16 0002020 9 0.23    
17 1001022 8 0.2    
18 1002120 6 0.15    
CCS2, circular consensus sequencing 2; SVs, structural variations; SMV, simeprevir; DCV, daclatasvir; 
ASV, asunaprevir; SOF, sofosbuvir; LDV, ledipasvir; asorting by frequency of each haplotype in descending 
order; bpercentage for the total number of the filtered ≥5-pass CCS2 reads in the sample. 
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Supplementary Table S4. All of the coded haplotypes in each sample (continued). 
sample# #9-SMV-pre     #9-SMV-post     
ranka haplotype 
# of 
CCS2 
%b haplotype 
# of 
CCS2 
%b 
1 0001000 6,131 97.97 0201000 3,641 98.99 
2 0021000 19 0.3 0201002 10 0.27 
3 0001002 17 0.27 0201200 8 0.22 
4 0001001 14 0.22 2201000 5 0.14 
5 2001000 11 0.18 0202000 4 0.11 
6 0201000 11 0.18 0201020 4 0.11 
7 1001000 10 0.16    
8 0001100 10 0.16    
9 0001200 9 0.14    
10 0001010 8 0.13    
11 0001020 7 0.11    
CCS2, circular consensus sequencing 2; SVs, structural variations; SMV, simeprevir; DCV, daclatasvir; 
ASV, asunaprevir; SOF, sofosbuvir; LDV, ledipasvir; asorting by frequency of each haplotype in descending 
order; bpercentage for the total number of the filtered ≥5-pass CCS2 reads in the sample. 
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Supplementary Table S4. All of the coded haplotypes in each sample (continued). 
sample# #9-DCV/ASV-pre     #9-DCV/ASV-post     
ranka haplotype 
# of 
CCS2 
%b haplotype 
# of 
CCS2 
%b 
1 0201000 2,518 46.17 0202012 9,837 99.16 
2 0001000 2,211 40.54 2202012 22 0.22 
3 0201010 418 7.66 0202212 17 0.17 
4 0001010 152 2.79 0202022 12 0.12 
5 0101000 33 0.61    
6 0201002 17 0.31    
7 0201020 13 0.24    
8 0001020 12 0.22    
9 0001002 12 0.22    
10 2201000 6 0.11    
11 2001000 6 0.11    
CCS2, circular consensus sequencing 2; SVs, structural variations; SMV, simeprevir; DCV, daclatasvir; 
ASV, asunaprevir; SOF, sofosbuvir; LDV, ledipasvir; asorting by frequency of each haplotype in descending 
order; bpercentage for the total number of the filtered ≥5-pass CCS2 reads in the sample. 
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Supplementary Table S4. All of the coded haplotypes in each sample (continued). 
sample# #9-SOF/LDV-pre     #10-SMV-pre     
ranka haplotype 
# of 
CCS2 
%b haplotype 
# of 
CCS2 
%b 
1 0202000 5,768 67.41 1002020 6,685 96.56 
2 0222000 2,277 26.61 1002000 120 1.73 
3 0222020 180 2.1 1002022 25 0.36 
4 0202020 132 1.54 0002020 24 0.35 
5 0202002 29 0.34 1002220 15 0.22 
6 0222012 28 0.33 1202020 10 0.14 
7 0222002 25 0.29 1001020 10 0.14 
8 0202200 22 0.26 1001022 8 0.12 
9 0222001 18 0.21    
10 0202100 15 0.18    
11 2202000 14 0.16    
12 0202010 10 0.12    
CCS2, circular consensus sequencing 2; SVs, structural variations; SMV, simeprevir; DCV, daclatasvir; 
ASV, asunaprevir; SOF, sofosbuvir; LDV, ledipasvir; asorting by frequency of each haplotype in descending 
order; bpercentage for the total number of the filtered ≥5-pass CCS2 reads in the sample. 
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Supplementary Table S4. All of the coded haplotypes in each sample (continued). 
sample# #10-SMV-post     #10-DCV/ASV-pre     
ranka haplotype 
# of 
CCS2 
%b haplotype 
# of 
CCS2 
%b 
1 1202020 6,507 92.1 1202020 7,041 98 
2 0202020 349 4.94 1202000 86 1.2 
3 1202000 133 1.88 1202022 23 0.32 
4 1202022 20 0.28    
5 1202220 11 0.16    
6 2202020 9 0.13    
CCS2, circular consensus sequencing 2; SVs, structural variations; SMV, simeprevir; DCV, daclatasvir; 
ASV, asunaprevir; SOF, sofosbuvir; LDV, ledipasvir; asorting by frequency of each haplotype in descending 
order; bpercentage for the total number of the filtered ≥5-pass CCS2 reads in the sample. 
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Supplementary Table S4. All of the coded haplotypes in each sample (continued). 
sample# #10-DCV/ASV-post     #10-SOF/LDV-pre     
ranka haplotype 
# of 
CCS2 
%b haplotype 
# of 
CCS2 
%b 
1 1202022 9,774 98.29 1002022 11,754 98.99 
2 1202002 87 0.87 1202022 38 0.32 
3 1202222 25 0.25 1002020 37 0.31 
4 2202022 15 0.15    
CCS2, circular consensus sequencing 2; SVs, structural variations; SMV, simeprevir; DCV, daclatasvir; 
ASV, asunaprevir; SOF, sofosbuvir; LDV, ledipasvir; asorting by frequency of each haplotype in descending 
order; bpercentage for the total number of the filtered ≥5-pass CCS2 reads in the sample. 
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Supplementary Table S4. All of the coded haplotypes in each sample (continued). 
sample# #11-SMV-pre     #11-DCV/ASV-pre     
ranka haplotype 
# of 
CCS2 
%b haplotype 
# of 
CCS2 
%b 
1 0010020 2,714 98.23 0210020 6,216 98.84 
2 0010022 18 0.65 0210022 24 0.38 
3 0011020 6 0.22 2210020 11 0.17 
4 0010220 6 0.22 0220020 11 0.17 
5 0110020 5 0.18 0210120 8 0.13 
6 0210020 4 0.14    
7 2010020 3 0.11    
8 0020020 3 0.11    
9 0012020 3 0.11    
CCS2, circular consensus sequencing 2; SVs, structural variations; SMV, simeprevir; DCV, daclatasvir; 
ASV, asunaprevir; SOF, sofosbuvir; LDV, ledipasvir; asorting by frequency of each haplotype in descending 
order; bpercentage for the total number of the filtered ≥5-pass CCS2 reads in the sample. 
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Supplementary Table S4. All of the coded haplotypes in each sample (continued). 
sample# #11-DCV/ASV-post     #11-SOF/LDV-pre     
ranka haplotype 
# of 
CCS2 
%b haplotype 
# of 
CCS2 
%b 
1 0211220 1,627 98.91 0201000 671 44.76 
2 0211222 8 0.49 0001000 419 27.95 
3 2211220 4 0.24 0201010 103 6.87 
4 0221220 3 0.18 1002020 42 2.8 
5 0210220 2 0.12 0211220 38 2.54 
6    0001010 37 2.47 
7    0202020 25 1.67 
8    0201020 17 1.13 
9    0210020 11 0.73 
10    1001000 10 0.67 
11    0202220 10 0.67 
12    0202000 9 0.6 
13    0201200 9 0.6 
14    0101000 9 0.6 
15    0210220 8 0.53 
16    0201220 7 0.47 
17    0010020 7 0.47 
18    0002020 7 0.47 
19    0211020 5 0.33 
20    0201100 5 0.33 
21    1202020 3 0.2 
22    0101010 3 0.2 
23    0021000 3 0.2 
24    2001010 2 0.13 
25    1002000 2 0.13 
26    0221000 2 0.13 
27    0212220 2 0.13 
28    0211000 2 0.13 
29    0202002 2 0.13 
30    0201012 2 0.13 
31    0201002 2 0.13 
32    0002000 2 0.13 
33    0001100 2 0.13 
34    0001020 2 0.13 
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CCS2, circular consensus sequencing 2; SVs, structural variations; SMV, simeprevir; DCV, daclatasvir; 
ASV, asunaprevir; SOF, sofosbuvir; LDV, ledipasvir; asorting by frequency of each haplotype in descending 
order; bpercentage for the total number of the filtered ≥5-pass CCS2 reads in the sample. 
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Supplementary Table S4. All of the coded haplotypes in each sample (continued). 
sample# #12-SMV-pre     #12-SMV-post     
ranka haplotype 
# of 
CCS2 
%b haplotype 
# of 
CCS2 
%b 
1 0001112 4,642 64.16 0211100 2,268 31.18 
2 0011112 2,516 34.78 2211100 1,950 26.81 
3 2001112 15 0.21 0201102 1,149 15.8 
4 0001012 11 0.15 0201112 831 11.43 
5    2111100 293 4.03 
6    2201102 116 1.59 
7    0211102 96 1.32 
8    0201100 83 1.14 
9    2201112 71 0.98 
10    0111100 56 0.77 
11    0001112 45 0.62 
12    2211102 39 0.54 
13    2201100 33 0.45 
14    1211100 14 0.19 
15    0211112 14 0.19 
16    0201110 13 0.18 
17    0101112 13 0.18 
18    0011100 12 0.16 
19    0001102 12 0.16 
20    2211112 11 0.15 
21    2101112 11 0.15 
22    0202100 10 0.14 
23    0221112 9 0.12 
CCS2, circular consensus sequencing 2; SVs, structural variations; SMV, simeprevir; DCV, daclatasvir; 
ASV, asunaprevir; SOF, sofosbuvir; LDV, ledipasvir; asorting by frequency of each haplotype in descending 
order; bpercentage for the total number of the filtered ≥5-pass CCS2 reads in the sample. 
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Supplementary Table S4. All of the coded haplotypes in each sample (continued). 
sample# #12-DCV/ASV-pre     #12-DCV/ASV-post     
ranka haplotype 
# of 
CCS2 
%b haplotype 
# of 
CCS2 
%b 
1 0001112 1,590 24.42 0202112 402 64.01 
2 0211100 1,341 20.59 0202100 39 6.21 
3 2111100 1,007 15.46 0202110 34 5.41 
4 2211100 600 9.21 0210200 31 4.94 
5 0201112 504 7.74 0202102 16 2.55 
6 0011100 272 4.18 0202200 15 2.39 
7 0111100 157 2.41 0102112 14 2.23 
8 0101112 120 1.84 0202212 13 2.07 
9 0211102 86 1.32 0211112 12 1.91 
10 2101112 67 1.03 0202210 7 1.11 
11 2201112 57 0.88 0202012 7 1.11 
12 2001112 44 0.68 0202000 6 0.96 
13 2011100 42 0.64 0211100 5 0.8 
14 0011102 41 0.63 0202202 5 0.8 
15 0001100 41 0.63 0211110 3 0.48 
16 0001110 40 0.61 0211102 3 0.48 
17 0201100 39 0.6 1202112 2 0.32 
18 0211112 35 0.54 0221112 2 0.32 
19 2111102 34 0.52 2211112 1 0.16 
20 0201110 34 0.52 0222100 1 0.16 
CCS2, circular consensus sequencing 2; SVs, structural variations; SMV, simeprevir; DCV, daclatasvir; 
ASV, asunaprevir; SOF, sofosbuvir; LDV, ledipasvir; asorting by frequency of each haplotype in descending 
order; bpercentage for the total number of the filtered ≥5-pass CCS2 reads in the sample. 
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Supplementary Table S4. All of the coded haplotypes in each sample (continued). 
sample# #12-DCV/ASV-pre     #12-DCV/ASV-post     
ranka haplotype 
# of 
CCS2 
%b haplotype 
# of 
CCS2 
%b 
21 0001102 33 0.51 0212212 1 0.16 
22 2211102 26 0.4 0212110 1 0.16 
23 0011112 21 0.32 0211210 1 0.16 
24 1211100 20 0.31 0211012 1 0.16 
25 0211110 16 0.25 0211010 1 0.16 
26 0011110 16 0.25 0211000 1 0.16 
27 0201102 15 0.23 0210202 1 0.16 
28 2101100 11 0.17 0202010 1 0.16 
29 0111102 11 0.17 0202002 1 0.16 
30 2211112 10 0.15 0102210 1 0.16 
31 2111110 10 0.15    
32 2111112 9 0.14    
33 2201102 8 0.12    
34 0221112 8 0.12    
35 2101102 7 0.11    
36 0202100 7 0.11    
37 0021112 7 0.11    
38 0002100 7 0.11    
CCS2, circular consensus sequencing 2; SVs, structural variations; SMV, simeprevir; DCV, daclatasvir; 
ASV, asunaprevir; SOF, sofosbuvir; LDV, ledipasvir; asorting by frequency of each haplotype in descending 
order; bpercentage for the total number of the filtered ≥5-pass CCS2 reads in the sample. 
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Supplementary Table S4. All of the coded haplotypes in each sample (continued). 
sample# #12-SOF/LDV-pre     
ranka haplotype 
# of 
CCS2 
%b 
1 0102112 3,396 76.31 
2 0002112 281 6.31 
3 0101112 124 2.79 
4 0102110 111 2.49 
5 0102100 89 2 
6 0102122 81 1.82 
7 0001112 76 1.71 
8 0102102 74 1.66 
9 0102012 40 0.9 
10 0102000 15 0.34 
11 0102212 14 0.31 
12 2102112 13 0.29 
13 1102112 10 0.22 
14 0202112 10 0.22 
15 0102002 9 0.2 
16 0102202 8 0.18 
17 0102010 7 0.16 
18 0102200 6 0.13 
19 0002102 6 0.13 
20 0112200 5 0.11 
21 0102120 5 0.11 
22 0002100 5 0.11 
23 0111112 4 0.09 
24 0101110 4 0.09 
25 0101100 4 0.09 
26 0002122 4 0.09 
27 0112202 3 0.07 
28 0101122 3 0.07 
29 0002110 3 0.07 
30 0002012 3 0.07 
CCS2, circular consensus sequencing 2; SVs, structural variations; SMV, simeprevir; DCV, daclatasvir; 
ASV, asunaprevir; SOF, sofosbuvir; LDV, ledipasvir; asorting by frequency of each haplotype in descending 
order; bpercentage for the total number of the filtered ≥5-pass CCS2 reads in the sample. 
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Supplementary Table S4. All of the coded haplotypes in each sample (continued). 
sample# #12-SOF/LDV-pre     
ranka haplotype 
# of 
CCS2 
%b 
31 1102100 2 0.04 
32 0112212 2 0.04 
33 0111102 2 0.04 
34 0111010 2 0.04 
35 0102210 2 0.04 
36 0101102 2 0.04 
37 0101012 2 0.04 
38 0002212 2 0.04 
39 0001110 2 0.04 
40 2102110 1 0.02 
41 2102000 1 0.02 
42 2002112 1 0.02 
43 1101112 1 0.02 
44 0202110 1 0.02 
45 0122112 1 0.02 
46 0112002 1 0.02 
47 0111110 1 0.02 
48 0101002 1 0.02 
49 0101000 1 0.02 
50 0012210 1 0.02 
51 0011112 1 0.02 
52 0011102 1 0.02 
53 0011012 1 0.02 
54 0002010 1 0.02 
55 0002000 1 0.02 
56 0001102 1 0.02 
57 0001100 1 0.02 
58 0001000 1 0.02 
CCS2, circular consensus sequencing 2; SVs, structural variations; SMV, simeprevir; DCV, daclatasvir; 
ASV, asunaprevir; SOF, sofosbuvir; LDV, ledipasvir; asorting by frequency of each haplotype in descending 
order; bpercentage for the total number of the filtered ≥5-pass CCS2 reads in the sample. 
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Supplementary Table S5. Summary of the CCS2 reads including SVs. 
sample# 
# of  
CCS2 reads  
including  
SVs 
# of  
CCS2 reads  
including  
DEL 
%a 
# of  
CCS2 reads  
including  
DUP 
%a 
# of  
CCS2 reads  
including  
INS 
%a 
# of  
CCS2 reads  
including  
INV 
%a 
# of  
CCS2 reads  
including  
INVDUP 
%a 
#1-DCV/ASV-pre 58 0 0 0 0 0 0 0 0 58 100 
#1-DCV/ASV-post 130 3 2.31 0 0 0 0 0 0 127 97.69 
#2-DCV/ASV-pre 220 0 0 2 0.91 0 0 0 0 218 99.09 
#2-DCV/ASV-post 5 0 0 0 0 0 0 0 0 5 100 
#3-DCV/ASV-pre 207 0 0 0 0 0 0 0 0 207 100 
#3-DCV/ASV-post 135 0 0 0 0 2 1.48 0 0 133 98.52 
#4-DCV/ASV-pre 213 0 0 6 2.82 0 0 0 0 207 97.18 
#4-DCV/ASV-post 374 0 0 0 0 0 0 0 0 374 100 
#5-DCV/ASV-pre 1,850 1,531 82.76 110 5.95 0 0 33 1.78 255 13.78 
#5-DCV/ASV-post 86 0 0 2 2.33 0 0 0 0 84 97.67 
#6-DCV/ASV-pre 221 143 64.71 0 0 0 0 0 0 101 45.7 
#6-DCV/ASV-post 26 0 0 0 0 0 0 0 0 26 100 
#7-DCV/ASV-pre 27 0 0 14 51.85 0 0 11 40.74 2 7.41 
#7-DCV/ASV-post 0 0 0 0 0 0 0 0 0 0 0 
#8-DCV/ASV-pre 318 316 99.37 0 0 0 0 0 0 2 0.63 
#8-DCV/ASV-post 69 69 100 0 0 0 0 0 0 0 0 
#9-SMV-pre 30 28 93.33 0 0 0 0 0 0 2 6.67 
#9-SMV-post 0 0 0 0 0 0 0 0 0 0 0 
#9-DCV/ASV-pre 4 4 100 0 0 0 0 0 0 0 0 
#9-DCV/ASV-post 0 0 0 0 0 0 0 0 0 0 0 
#9-SOF/LDV-pre 42 28 66.67 0 0 0 0 4 9.52 10 23.81 
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Supplementary Table S5. Summary of the CCS2 reads including SVs (continued). 
sample# 
# of  
CCS2 reads  
including  
SVs 
# of  
CCS2 reads  
including  
DEL %a 
# of  
CCS2 reads  
including  
DUP %a 
# of  
CCS2 reads  
including  
INS %a 
# of  
CCS2 reads  
including  
INV %a 
# of  
CCS2 reads  
including  
INVDUP %a 
#10-SMV-pre 0 0 0 0 0 0 0 0 0 0 0 
#10-SMV-post 22 22 100 0 0 0 0 0 0 0 0 
#10-DCV/ASV-pre 0 0 0 0 0 0 0 0 0 0 0 
#10-DCV/ASV-post 0 0 0 0 0 0 0 0 0 0 0 
#10-SOF/LDV-pre 0 0 0 0 0 0 0 0 0 0 0 
#11-SMV-pre 0 0 0 0 0 0 0 0 0 0 0 
#11-DCV/ASV-pre 0 0 0 0 0 0 0 0 0 0 0 
#11-DCV/ASV-post 5 0 0 0 0 0 0 0 0 5 100 
#11-SOF/LDV-pre 0 0 0 0 0 0 0 0 0 0 0 
#12-SMV-pre 2 2 100 0 0 0 0 0 0 0 0 
#12-SMV-post 739 739 100 0 0 0 0 0 0 0 0 
#12-DCV/ASV-pre 688 671 97.53 2 0.29 0 0 2 0.29 21 3.05 
#12-DCV/ASV-post 240 240 100 0 0 0 0 0 0 0 0 
#12-SOF/LDV-pre 548 540 98.54 4 0.73 0 0 0 0 4 0.73 
CCS2, circular consensus sequencing 2; SVs, structural variations; DEL, deletion; DUP, duplication; INS, insertion; INV, inversion; SMV, simeprevir; DCV, daclatasvir; ASV, 
asunaprevir; SOF, sofosbuvir; LDV, ledipasvir; apercentage for the total number of the ≥5-pass CCS2 reads in the sample.  
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Supplementary Table S6. List of structural variations existing at ≥1% in the sample. 
SV# Sample# SV type 
Predicted start 
positiona 
Predicted end 
positiona 
Predicted 
SV sizea 
# of supporting CCS2 
reads at pre-treatment 
%c 
# of supporting CCS2 
reads at treatment failure 
%c 
1 #2-DCV/ASV-pre INVDUP 4,201 4,246 45 117 1.06 0 0 
2 #4-DCV/ASV-pre INVDUP 5,516 5,612 96 124 1.13 0 0 
3 #4-DCV/ASV-post INVDUP 5,521 5,606 85 0 0 239 2.17 
4 #5-DCV/ASV-pre DEL 3,569 5,979 2,410 1,527 13.9 0 0 
5 #6-DCV/ASV-pre DEL 4,726 5,814 1,088 118 1.07 0 0 
6 #8-DCV/ASV-pre DEL 5,267 6,407 1,140 316 2.87 0 0 
7 #12-SMV-post DEL 5,299 5,722 423 0 0 625 5.68 
8 #12-DCV/ASV-pre DEL 4,479 5,797 1,318 192 1.75 0 0 
9 #12-DCV/ASV-pre DEL 5,267 6,404 1,137 128 1.16 56 0.51 
10 #12-SOF/LDV-pre DEL 3,644 4,763 1,119 540 4.91 -b -b 
CCS2, circular consensus sequencing 2; SVs, structural variations; SMV, simeprevir; DCV, daclatasvir; ASV, asunaprevir; SOF, sofosbuvir; LDV, ledipasvir; 
DEL, deletion; abp; bNo data because we did not extract the samples after SOF+LDV treatment; cpercentage for the total number of the ≥5-pass CCS2 reads in 
the sample.  
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Supplementary Table S7. Patients’ information. 
Case age Sex Viral genotype 
#1 75 female 1b 
#2 61 female 1b 
#3 63 female 1b 
#4 78 male 1b 
#5 55 female 1b 
#6 63 female 1b 
#7 74 female 1b 
#8 63 male 1b 
#9 63 male 1b 
#10 63 male 1b 
#11 64 male 1b 
#12 68 male 1b 
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Supplementary Table S8. PCR primer set for sequencing the region between NS3 and NS5A genes. 
Primer# Sequence 
Start 
positiona 
Stop 
positiona 
Objectives 
Fw1 ACAGGTCGGGACAAGAACCAG 3,471 3,491 RT-PCR for NS3-NS5A region (for cases #1-#8) 
Fw2 ACAAGAACCAGGTCGATGGGGAG 3,481 3,503 nested PCR for NS3-NS5A region (for cases #1-#8) 
Fw3 GGAGATACTTCTAGGACCGGCCGAT   3,353 3,377 RT-PCR for NS3-NS5A region (for cases #9-#12) 
Fw4 GCCTATCACGGCCTATTCCCAACAA   3,410 3,434 nested PCR for NS3-NS5A region (for cases #9-#12) 
Rv1 CCCGTCACGTAGTGGAAATC 6,621 6,640 RT-PCR for NS3-NS5A region (for cases #1-#8) 
Rv2 GCGTAACCTCCACGTACTCC 6,593 6,612 nested PCR for NS3-NS5A region (for cases #1-#8) 
Rv3 CGTAGGAGAGGTTTGCACACTGGAG  6,730 6,754 RT-PCR for NS3-NS5A region (for cases #9-#12) 
Rv4 CATGGGCATTTCACGTTGTCAGTGG   6,646 6,670 nested PCR for NS3-NS5A region (for cases #9-#12) 
athe position based on HCV genome sequence "D90208.1"; RT, reverse transcription; PCR, polymerase chain reaction 
65 
 
Supplementary Figure S1. Mean coverage of ≥5pass CCS2 reads for HCV genome. 
BLASR version 1.3.1 mapped ≥ 5pass CCS2 reads to HCV genome sequence (accession no. 
D90208.1) with default parameter and GATK version 3.2.2 calculated the coverage of ≥5pass CCS2 
reads with parameter “-T DepthOfCoverage -DBQ 0). X-axis demonstrates the position based on HCV 
reference genome. Y-axis means the coverage of the CCS2 reads aligned to the position. The CCS2 
reads covered the region between NS3 and NS5A genes at >7,000 coverage on average.
66 
 
 
67 
 
Supplementary Figure S2. The mapping of CCS2 supporting ≥1% SVs to HCV genome. 
The mapping software ngmlr version 0.2.6 aligned ≥5-pass CCS reads to HCV genome (accession no. 
D90208.1), and the structural variation (SV) calling software Sniffles detected ≥30-bp SVs. Of the 
called SVs, we selected the 10 examples existing at ≥1% in the samples, which were not shown in 
Figure 4. In each panel, the upper schema shows the HCV genome structure with SV at NS3 through 
NS5A genes. The red symbols stand for the region SV occurred in. Especially, the inverted gene 
symbols represent inversion occurring in the gene and the boxes with dash lines means deletion. The 
positions shown in the upper figure are based on the reference. The lower image demonstrates the 
alignment of the representative reads supporting the SVs in MUMmer program. X-axis shows the 
position of the HCV reference genome. Y-axis shows the position of the reads harbouring SVs. The 
purple solid line means the alignment for HCV reference genome without SVs. The blue solid line 
demonstrates the inverted alignment for HCV reference genome. (A). 45-bp INVDUP within the 
sample #2-DCV/ASV-pre. (B). 96-bp INVDUP within the sample #4-DCV/ASV-pre. (C). 85-bp 
INVDUP within #4-DCV/ASV-post. (D). 2 410-bp deletion within #5-DCV/ASV-pre. (E). 1 088-bp 
deletion within #6-DCV/ASV-pre. (F). 1 140-bp deletion within ##8-DCV/ASV-pre. (G). 1 318-bp 
deletion within #12-DCV/ASV-pre. (H). 1 137-bp deletion within #12-DCV/ASV-pre.  
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The NS3-to-NS5A long amplicon RT-PCR amplification 
Total RNA was extracted from 140 mL of serum using a QIAamp Viral RNA Mini kit (QIAGEN, 
Valencia, CA). HCV sequences spanning NS3 and NS5A regions (3120 bp) of the HCV genome for 
serum samples were reverse-transcribed in a volume of 20 µL with the One step RT-PCR Kit AMV or 
the PrimeScript One Step RT-PCR kit ver.2 (Takara Bio, Otsu, Japan) according to the manufacturer’s 
protocol. For nested PCR, the products of RT-PCR were amplified using Phusion High-Fidelity DNA 
polymerase (FINZYMES, Espoo, Finland) or the PrimeStar HS kit (Takara Bio) according to the 
manufacturer’s protocol by using HCV-specific primers shown in Supplementary Table S8. 
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